Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies

Over the past 50 years, breast cancer immunotherapy has emerged as an active field of research, generating novel, targeted treatments for the disease. Immunotherapies carry enormous potential to improve survival in breast cancer, particularly for the subtypes carrying the poorest prognoses. Here, we review the mechanisms by which cancer evades immune destruction as well as the history of breast cancer immunotherapies and recent developments, including clinical trials that have shaped the treatment of the disease with a focus on cell therapies, vaccines, checkpoint inhibitors, and oncolytic viruses.

Automated summary

Breast cancer immunotherapy, as an active field of research over the past 50 years, has shown great potential in improving survival rates for patients. Researchers are exploring how breast cancer evades immune destruction and developing new treatment options such as cell therapies, vaccines, checkpoint inhibitors, and oncolytic viruses.